SIGA's mpox indication loss creates tactical mispricing setup amid strong cash and pipeline catalysts

The specific catalyst is clear: the European Medicines Agency's expert committee (CHMP) has recommended that SIGA's tecovirimat (TPOXX) should no longer be used for mpox treatment. This decision, announced last Friday, follows a review of data from four clinical trials that found the drug did not heal skin lesions faster than a placebo in people with active mpox, nor did it improve other key outcomes like pain relief or viral clearance CHMP's recommendation for mpox follows a review of data from four studies. This is a direct clinical downgrade for a key commercial indication.

The immediate trading setup hinges on the stock's recent sensitivity to disease headlines. Just months ago, SIGA's shares surged nearly 27% on news that the World Health Organization had declared mpox a public health emergency Siga Technologies (SIGA)... saw its stock surge nearly 27% on Wednesday as the World Health Organization (WHO) declared Mpox a public health emergency. That move was driven by a spike in retail investor interest and sentiment, showing the stock's price is highly reactive to mpox-related news. The EMA recommendation now provides a stark negative headline that could trigger a sharp reversal.

The tactical thesis is that this recommendation is a clear negative catalyst that likely overreacts to the clinical data. While the loss of the mpox indication is a setback, the commercial impact is likely to be phased and limited. Tecovirimat remains approved for smallpox, cowpox, and vaccine complications-uses that are critical for government stockpiles and do not rely on mpox outbreaks This recommendation does not affect the other authorised uses of Tecovirimat SIGA. The drug's value is anchored in its role as a first-line smallpox countermeasure, a position solidified by its use in a recent $113 million U.S. government contract option Last month, the company's stock received a boost after the U.S. Department of Health and Human Services exercised a $113 million contract option.

Therefore, if the stock's drop following the EMA news is disproportionate to the actual, phased commercial impact on SIGA's overall business, it creates a potential tactical mispricing opportunity. The event-driven setup is to watch for whether the market's reaction is an overreaction to a single indication loss, or a rational reassessment of the drug's broader utility.

Assessing the Financial and Pipeline Risk

The immediate financial risk from the EMA recommendation is to future European government procurement and any private market sales of tecovirimat for mpox. However, the direct P&L impact is quantifiable and limited. In 2025, SIGA's total product revenue was about $88 million, driven almost entirely by deliveries to the U.S. Strategic National Stockpile. The mpox indication was a key driver in Europe, but its commercial contribution was a subset of that total. The full impact will be phased, as European governments may take time to reassess their stockpiling strategies and procurement decisions.

The company's near-term financial resilience provides a crucial buffer. SIGA finished 2025 with roughly $155 million in cash and no debt. This strong balance sheet, coupled with net income of about $23 million for the year, means the company can weather a period of reduced European mpox sales without immediate financial strain. The procurement-driven business model means quarterly results can vary, but the cash position offers runway to navigate this regulatory shift.

Management's pipeline focus points to alternative growth drivers that are separate from the mpox indication. The company has a targeted FDA submission for a post-exposure prophylaxis (PEP) indication within 12 months. This is a distinct, non-mpox use case that could open a new commercial channel. Other near-term catalysts include a pediatric oral-suspension phase I readout later this year and a new $13 million Asia-Pacific multi-year order received in January. The company also expects about $26 million of U.S. government orders to ship in 2026, providing a steady revenue anchor.

The bottom line is that while the EMA recommendation is a negative catalyst for one specific use case, it does not threaten SIGA's core financial stability or its primary revenue stream. The tactical mispricing opportunity hinges on whether the market's reaction overestimates the speed and scale of the commercial impact, ignoring the company's cash cushion and its pipeline of non-mpox initiatives.

Valuation and Near-Term Catalysts

The tactical mispricing thesis now faces a critical test: whether the market's reaction is a temporary overhang or the start of a broader reassessment. The fundamental risk is that negative trial data, like the recent NIH STOMP trial, will accelerate the loss of tecovirimat's utility in other key markets, including the United States. This could undermine the drug's value beyond Europe, threatening the commercial foundation of SIGA's business.

The near-term catalysts are clear and will dictate the stock's direction. For a recovery, the primary trigger is a successful FDA submission for the post-exposure prophylaxis (PEP) indication within the next 12 months. This would demonstrate the company's ability to pivot to a new, non-mpox use case and provide a tangible growth catalyst separate from the current regulatory headwinds. Another near-term positive is the expected $26 million of U.S. government orders to ship in 2026, which offers a steady revenue anchor. The pediatric oral-suspension phase I readout later this year is also a potential catalyst for pipeline validation.

The main risk is a broader loss of confidence. Investors must watch for updates on the three other ongoing mpox trials-UNITY, Platinum-CAN, and EPOXI-as their outcomes could further erode the drug's clinical profile. More critically, any regulatory review in the U.S. or other major markets that follows the EMA's lead would signal a systemic shift in the drug's approved utility. The company's recent $13 million Asia-Pacific multi-year order is a positive sign of continued international demand, but it does not offset the potential for a coordinated global withdrawal from the mpox indication.

The valuation setup is now binary. If the FDA PEP submission succeeds and government orders continue, the stock's recent drop may look like a tactical buying opportunity. If, however, the negative trial data leads to a coordinated loss of mpox use across key markets, the fundamental risk becomes the dominant story. The event-driven opportunity hinges on the market correctly weighing the limited, phased commercial impact against the more severe, systemic threat to the drug's utility.